MTEX Mannatech (MTEX) Insider Trading, Ownership & Congress Trades
Pharma & Biotech · Medicinal chemicals & botanical products · CIK 0001056358
SEC filings
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
5
13F, latest reported quarter
What the filings say about MTEX
Insiders, 180 days
+$62.2K net bought
2 buyers
Mannatech insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
Over the last 180 days, MANNATECH INC insiders bought a net $62.2K of stock across 18 Form 4 purchases and sales, with 2 insiders buying. Source: SEC Form 4 filings, as of 2026-10-28.
Insider
Filed
Shares
Value
Since filing
Context
- 4 earlier Form 4 trades (code P or S) here by this insider (1 buy, 3 sales), the last on May 19, 2026.
- The trade is 4.0% of the 70,000 shares held after it.
- 1 other insider bought within 30 days.
- 5 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director JOBE LARRY A bought about $11.5K of MTEX on May 20, 2026; 1 other insider bought within 30 days and 5 funds added in the latest 13F quarter.Context
- 3 earlier Form 4 trades (code P or S) here by this insider (3 sales), the last on Sep 9, 2024.
- The trade is 7.4% of the 67,197 shares held after it.
- 1 other insider bought within 30 days.
- 5 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director JOBE LARRY A bought about $21.0K of MTEX on May 19, 2026, the largest insider purchase at the company since 2024; 1 other insider bought within 30 days and 5 funds added in the latest 13F quarter.Context
- 7 earlier Form 4 trades (code P or S) here by this insider (7 sales), the last on Dec 8, 2022.
- The trade is 21.3% of the 33,333 shares held after it.
- 1 other insider bought within 30 days.
- 5 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Robbins Kevin Andrew bought about $29.6K of MTEX on May 19, 2026, the largest insider purchase at the company since 2024; 1 other insider bought within 30 days and 5 funds added in the latest 13F quarter.Context
- 2 earlier Form 4 trades (code P or S) here by this insider (2 sales), the last on May 22, 2024.
- The trade is 29.8% of the 54,721 shares held after it.
- No other insider sold within 30 days.
- 5 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director JOBE LARRY A sold about $126.2K of MTEX on Sep 9, 2024, the largest insider sale at the company on our record; 5 funds added in the latest 13F quarter.Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 5.4% of the 299,197 shares held after it.
- No other insider bought within 30 days.
- 5 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Rameson Tyler bought about $126.2K of MTEX on Sep 9, 2024, the largest insider purchase at the company on our record; 5 funds added in the latest 13F quarter.18 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
net +$62.2K over 180 days
more than 74% of Pharma & Biotech
Congress
no House purchase disclosed in the last 12 months
Funds
5 funds bought in last quarter
below 95% of Pharma & Biotech
Revenue
-8.3% year over year
below 64% of Pharma & Biotech
Margin
-14.1% net margin
more than 61% of Pharma & Biotech
Buybacks
no share repurchases reported
Short interest
1.5% of the float short (float per yahoo 2026-10-27) · 1.0 days to cover · settled 2026-10-15
below 79% of Pharma & Biotech
What changed in the last 30 days
Oct 28Insider buying stopped: no purchases in 90 days after 3 in the prior 90
Why it matters
The absence is the signal: 3 purchases in one 90-day window and none in the next is a change of behaviour, not a filing.
Watch MTEX
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-7.7%12M
Insider buy13D/G stake
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns MTEX: institutional holders (13F)
13F holdings, latest reported quarter
52,163 sh
$271.8K
41,528 sh
$216.4K
30,078 sh
$156.7K
19,090 sh
$99.5K
2,679 sh
$14.0K
Congress trades in MTEX
No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.
Activist and 5% holders (13D/13G)
13D: intends to influence · 13G: passive
TOTH ROBERT
Activist 13D · 2026-04-24
5.1%
MTEX planned insider sales (Form 144)
No planned-sale notices
No insider has filed to sell. Watch this after a run-up.
MTEX mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
Fidelity Extended Market Index Fund
$25.6K position · as of 2026-05-31
0.0%
VANGUARD INSTITUTIONAL TOTAL STOCK MARKET INDEX FUND
$14.0K position · as of 2026-06-30
0.0%
VANGUARD EXTENDED MARKET INDEX FUND
$38.6K position · as of 2026-06-30
0.0%
Fidelity Nasdaq Composite Index Fund
$7.9K position · as of 2026-05-31
0.0%
U.S. Targeted Value Portfolio
$4.6K position · as of 2026-07-31
0.0%
Fidelity Series Total Market Index Fund
$9.6K position · as of 2026-05-31
0.0%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Executive pay vs shareholder return · Landen Fredrick
CEO pay, headline and as actually paid, against the company's
return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2025
$368.8K
$368.8K
$144.8K
-39%
n/a
2024
$641.1K
$641.1K
$90.4K
+66%
n/a
2023
$491.0K
$491.0K
$313.1K
-53%
n/a
Tagged by the company under SEC Item 402(v). Returns are
cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders are net buyers of their own stock.
The record shows a net $62.2K bought by insiders over 180 days, 5 funds added last quarter. Each figure is a federal filing, dated the day it went public.
MTEX financials
Revenue growth
-8.3%
XBRL, annual
Net margin
-14.1%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$107.4M
four quarters, 2025-07-01 to 2026-06-30
Revenue, TTM MTEX
| FY Dec 2025 | $108.0M |
| FY Dec 2024 | $117.9M |
| FY Dec 2023 | $132.0M |
| FY Dec 2022 | $137.2M |
| FY Dec 2021 | $159.8M |
| Jun 2026 | $26.6M |
| Mar 2026 | $24.9M |
| Dec 2025 | $26.6M |
| Sep 2025 | $29.2M |
| Jun 2025 | $25.7M |
| Mar 2025 | $26.6M |
| Dec 2024 | $29.0M |
| Sep 2024 | $31.7M |
At each fiscal year end
Single quarter
Net margin, TTM
-6.9%
net income over revenue, 2025-07-01 to 2026-06-30
Net margin, TTM MTEX
| FY Dec 2025 | -14.1% |
| FY Dec 2024 | +2.1% |
| FY Dec 2023 | -1.7% |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | +3.8% |
| Mar 2026 | +3.8% |
| Dec 2025 | -42.4% |
| Sep 2025 | +6.6% |
| Jun 2025 | -16.8% |
| Mar 2025 | -5.8% |
| Dec 2024 | +7.8% |
| Sep 2024 | -1.0% |
At each fiscal year end
Single quarter
Free cash flow, TTM
$1.6M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Free cash flow, TTM MTEX
| FY Dec 2025 | -$4.3M |
| FY Dec 2024 | $2.0M |
| FY Dec 2023 | -$3.1M |
| FY Dec 2022 | -$3.7M |
| FY Dec 2021 | $10.1M |
| Jun 2026 | -$802.0K |
| Mar 2026 | $997.0K |
| Dec 2025 | -$463.0K |
| Sep 2025 | $1.9M |
| Jun 2025 | -$3.9M |
| Mar 2025 | -$1.9M |
| Dec 2024 | -$113.0K |
| Sep 2024 | $3.0M |
At each fiscal year end
Single quarter
Debt to equity
n/a
equity is zero or negative, the ratio has no meaning
Debt to equity MTEX
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | 0.42x |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
0.89x
TTM operating cash flow over long-term debt only, 2026-06-30
Cash flow to debt MTEX
| FY Dec 2025 | -1.08x |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | 0.89x |
| Mar 2026 | -0.17x |
| Dec 2025 | -1.08x |
| Sep 2025 | -1.00x |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
-1,488%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on equity MTEX
| FY Dec 2025 | -896.5% |
| FY Dec 2024 | +26.2% |
| FY Dec 2023 | -17.8% |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | -1,488% |
| Mar 2026 | -1,253% |
| Dec 2025 | -896.5% |
| Sep 2025 | -19.4% |
| Jun 2025 | -55.0% |
| Mar 2025 | -2.3% |
| Dec 2024 | +26.2% |
| Sep 2024 | -14.4% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
-26.9%
TTM net income over ending balance 2026-06-30
Return on assets MTEX
| FY Dec 2025 | -46.0% |
| FY Dec 2024 | +6.5% |
| FY Dec 2023 | -4.9% |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | -26.9% |
| Mar 2026 | -38.2% |
| Dec 2025 | -46.0% |
| Sep 2025 | -4.4% |
| Jun 2025 | -10.0% |
| Mar 2025 | -0.5% |
| Dec 2024 | +6.5% |
| Sep 2024 | -3.6% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
n/a
effective tax rate 248%, not meaningful
Return on invested capital MTEX
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
+25.2%
operating income (EBIT proxy) over ending balance 2026-06-30 minus current liabilities
Return on capital employed MTEX
| FY Dec 2025 | -3.2% |
| FY Dec 2024 | +9.3% |
| FY Dec 2023 | -5.6% |
| FY Dec 2022 | -1.7% |
| FY Dec 2021 | +28.8% |
| Jun 2026 | +25.2% |
| Mar 2026 | +1.9% |
| Dec 2025 | -3.2% |
| Sep 2025 | +3.7% |
| Jun 2025 | -3.6% |
| Mar 2025 | -1.6% |
| Dec 2024 | +9.3% |
| Sep 2024 | -2.0% |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
P/E, trailing MTEX
| FY Dec 2025 | n/a |
| FY Dec 2024 | 10.10x |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | 8.14x |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | 10.10x |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
$13.4M
market value at close 2026-10-26 on 2026-08-05 shares, plus long-term debt only, 2026-06-30, minus cash 2026-06-30
Enterprise value MTEX
| FY Dec 2025 | $12.2M |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | $6.8M |
| Mar 2026 | $6.7M |
| Dec 2025 | $12.2M |
| Sep 2025 | $14.7M |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
+9.6%
TTM free cash flow over market value at close 2026-10-26
FCF yield MTEX
| FY Dec 2025 | -27.5% |
| FY Dec 2024 | +7.8% |
| FY Dec 2023 | -20.7% |
| FY Dec 2022 | -11.0% |
| FY Dec 2021 | +13.7% |
| Jun 2026 | +15.9% |
| Mar 2026 | -13.3% |
| Dec 2025 | -27.5% |
| Sep 2025 | -21.0% |
| Jun 2025 | -15.9% |
| Mar 2025 | -9.8% |
| Dec 2024 | +7.8% |
| Sep 2024 | +3.8% |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
PEG, trailing MTEX
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | 0.12x |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-12 | 2024-12 | 2023-12 | 2022-12 | |
|---|---|---|---|---|
| Revenue | $108.0M | $117.9M | $132.0M | $137.2M |
| Gross profit | $81.0M | $91.5M | $102.9M | $104.1M |
| Operating income | -$426.0K | $1.4M | -$964.0K | -$405.0K |
| Net income | -$15.2M | $2.5M | -$2.2M | -$4.5M |
| EPS (diluted) | -8.00 | 1.32 | -1.20 | -2.35 |
| Operating cash flow | -$3.0M | $2.3M | -$2.4M | -$2.6M |
| Cash | $6.2M | $11.4M | $7.7M | $13.8M |
| Long-term debt | $2.8M | n/a | n/a | n/a |
| Buybacks | n/a | $0 | $176.0K | $2.0M |
| Dividends paid | n/a | $0 | $748.0K | $1.5M |
SEC XBRL, fiscal years, as known on 2026-10-28
MTEX Stock Sonar score 6/7 axes
Find similar shapesCompareMTEX ranks highest on financial health (91st percentile) and risk and compliance (80th), and lowest on institutional and government (5th), among Pharma & Biotech peers.
6 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
MTEX filings, in plain words
Are Mannatech insiders buying or selling MTEX?
In the 180 days to 2026-10-28, Mannatech insiders were net buyers, a net $62.2K across purchases and sales reported on Form 4, by 2 buyers.
Read the full summary
In the 180 days to 2026-10-28, Mannatech insiders were net buyers of MTEX, a net $62.2K across purchases and sales reported on Form 4 by 2 buyers. The latest 5% ownership filing is a 13D by TOTH ROBERT, filed 2026-04-24, for 5.1% of the class. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
